Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 November 2019 | Story Legopheng Maphile | Photo Supplied
Open Access
Staff from the Library and Information Services of the UFS and the CUT

The Library and Information Services of the University of the Free State (UFS) and the Central University of Technology,Free State (CUT) jointly hosted an Open Science Colloquium on 19 November 2019. The colloquium was in response to the national and international developments in what is referred to as ‘the Open Access 2020 (OA2020) movement’. This movement calls on all parties involved in scholarly communication to take action to make their scholarly outputs open and freely available to all citizens of the world. It is a move against the current subscription-based model of publication, which has proved to be costly and unsustainable, and which limits access to knowledge to a few, making it unacceptable.

Welcoming more than 200 delegates to the UFS, Ms Betsy Eister, Director: Library and Information Services, referred to OA2020 as a disruption in the publishing arena.

Endorsing the Berlin Declaration on Open Access to Knowledge in the Sciences and Humanities

The colloquium comes as an endorsement of the Berlin Declaration on Open Access to Knowledge in the Sciences and Humanities that the two universities signed eight years ago. As signatories, the UFS and CUT have committed to the wide and free dissemination of its scholarship by means of open access platforms. This declaration was confirmed by the Rector and Vice-Chancellor, Prof Francis Petersen.  

“When the UFS signed the Berlin Declaration on Open Access to Knowledge in the Sciences and Humanities in 2011, this university committed itself to the wide and free dissemination of its scholarship by means of open access platforms. At that point, we have already made that commitment to open access platforms.”

Open access vs subscription

Prof Petersen said challenging the current status quo will bring equity into the system, which  will “ensure that our younger cohort of researchers and scholars have the ability to freely conduct research, to freely access material, so that we can produce high-quality researchers and scholars for our system”. 

Also present was Prof Ahmed Bawa, Chief Executive Officer of Universities South Africa, who echoed Prof Petersen’s message by making a case for management, researchers, libraries and research funders to work together to make OA2020 a reality. “These discussions are very important because it provides us with an opportunity to build international consensus on these things, which is critical in moving forward.”

Prof Ahmed Bawa

Prof Ahmed Bawa, Chief Executive Officer of Universities South Africa addressed delegates on the importance of open access. 

Mr Glenn Truran, Director of the South African Library and Information Consortium (SANLiC), and Ms Eister addressed the national and local roadmaps, respectively. SANLiC, a consortium that negotiates deals for electronic resource subscriptions on behalf of all 26 public universities and eight research councils, has already started transformative agreement negotiations with international publishing company Taylor and Francis. 

The colloquium ended with a declaration signed by members present, hoping that it would be signed by all concerned as a commitment to taking action towards open access.  The two universities will ultimately sign the OA2020 Expression of Interest.

• The UFS and CUT Libraries are thankful to Mr Gareth O’Neill and UFS colleagues (Mr Charlie Molepo and Mrs Cornelle Scheltema-Van Wyk), who shared information with the attendees on transformation agreements (also referred to as Plan S) and AmeliCA, respectively. Plan S deals with transformation agreements to be signed with publishers, which are about negotiations with publishers to change from subscription-based to open-access journal publishing models. Mr Molepo and Mrs Scheltema-Van Wyk showcased the open access model that the UFS Library has already implemented, which is what AmeliCA is all about. This involves the publication of nine accredited UFS journals on the Open Journals System platform, which enhance its discoverability and accessibility. It was also a pleasure to listen to Prof Abdon Atangana from the UFS Institute for Groundwater Studies – a classic example of an activist and beneficiary of open access publishing – who was recently named as one of the top-10 cited researchers in the Web of Science, thanks to open access publication.

Betsy Eister
Betsy Eister, Director: Library and Information Services at the UFS. 


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept